Alphamab Oncology's (HKG:9966) phase 3 clinical trial for the combination of the KN046 drug with nab-paclitaxel/gemcitabine for the treatment of unresectable or metastatic pancreatic ductal adenocarcinoma did not reach overall survival statistical endpoint, according to a Wednesday filing with the Hong Kong Stock Exchange.
The trial also reached the number of preset deaths, the filing said. Alphamab said it cannot guarantee it will be able to develop and market KN046 successfully.
Shares plunged over 38% in Hong Kong during Wednesday's morning trade.
Price (HKD): $2.88, Change: $-1.88, Percent Change: -39.50%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments